-
After 30 years and covering 2 million people, Harvard University has found the most life-prolonging recipe: 160 grams of fruits and 240 grams of vegetables per day
Time of Update: 2021-07-20
The results of the analysis are consistent with the results of the separate analysis of the NHS and HPFS cohorts, suggesting that about 5 servings of fruits and vegetables per day, that is, 2 servings of fruits and 3 servings of vegetables, the participants have the lowest risk of death .
-
Nature Sub-Journal: Scientists have successfully differentiated human heart-forming organoids
Time of Update: 2021-07-20
They developed a method that uses hPSC directed differentiation to generate complex and The highly structured three-dimensional heart forming organoid (HFO) can be used to study the early development of the heart and the development of the foregut .
-
Cell Sub-Journal: Obesity of pregnant women will affect children's cognitive and social impairment!
Time of Update: 2021-07-20
In short, the study clarified the mechanism link between maternal obesity and cognitive behavioral deficits in offspring, and proposed that increasing dietary fiber intake can significantly improve the neurodevelopment of offspring with cognitive and social deficits .
-
Where is the next Nugget spot?
Time of Update: 2021-07-20
B cell maturation antigen (BCMA) is not only one of the most popular targets for multiple myeloma, it is also a testing ground for tumor treatment platforms, which are becoming more and more mature in the field of tumors, such as antibody-drug conjugates (ADCs) , Bispecific antibodies and cell-based therapy .
-
Chinese Light: The R&D History of Crizotinib
Time of Update: 2021-07-19
Considering that the NH and C=O structures of hydroxyindole can bind to kinase through hydrogen bonds, Pfizer screened compounds with hydroxyindole structure and found that derivative 1 has strong inhibitory activity on c-Met kinase (IC50 =10 nmol·L-1), and at a concentration of 1 μmol·L-1, the growth of A549 cells can be completely prevented by inhibiting c-Met.
-
Hengrui Medicine's SHR-1707 treatment of Alzheimer's disease clinical trial approved
Time of Update: 2021-07-19
On March 10, the clinical trial application of Hengrui Pharmaceuticals SHR-1707 was approved by NMPA for the treatment of Alzheimer's disease (AD) .
According to a report released this year by Evaluate Vantage, a pharmaceutical market research organization, Aducanumab's global sales in 2026 will reach 4.
-
Hong Kong stocks pioneering pharmaceutical releases clinical trial results of Prokalamide in the treatment of severe patients with new coronary pneumonia
Time of Update: 2021-07-19
HK) released the clinical trial results of Prokalamide in the treatment of severely ill patients with COVID-19 .
In clinical trials, procrulamide reached the primary endpoint on day 14, indicating that the World Health Organization COVID-19 rating scale dropped from a baseline of 5.
-
Roche Actemra combined with Redecivir in the treatment of severe COVID-19 patients with phase III clinical failure
Time of Update: 2021-07-19
On March 10th, Genentech, a Roche subsidiary, announced that the phase III REMDACTA study evaluating the anti-inflammatory drug Actemra (tocilizumab, tocilizumab) combined with Veklury (remdesivir, remdesivir) for the treatment of patients with severe COVID-19 pneumonia did not meet the primary endpoint And key secondary endpoints .
-
The competitive landscape of clinical medication for relapsed or refractory DLBCL
Time of Update: 2021-07-18
DLBCL is the most common type of NHL, accounting for 39.
6% of newly diagnosed NHL each year and 80% of aggressive lymphomas .
-
The birth of Apixaban
Time of Update: 2021-07-18
Apixaban is a direct factor Xa (factor Xa, FXa) inhibitor. It is used as an anticoagulant to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It ca
-
AD new drug development "nine deaths and a lifetime" Eli Lilly and others continue to bet on Hengrui's entry, who can break through?
Time of Update: 2021-07-18
For the development of anti-Aβ antibodies, Roche's Crenezumab has failed in Phase III clinical trials, but it is still in the Phase II pipeline of Roche and is planned to be used to treat patients with familial Alzheimer's disease .
-
The controversial but successful listing of the AZ new crown vaccine started from which step did it go wrong?
Time of Update: 2021-07-17
Compared with Pfizer/BioNTech and Moderna's mRNA vaccine in a single country (focused in the United States), only a single large-scale phase III clinical trial with a unified process, AstraZeneca's new crown vaccine AZD1222 has conducted multiple independent clinical trials in different places .
-
Johnson & Johnson's psoriatic arthritis drug Tremfya has proven long-term efficacy in two-year trial
Time of Update: 2021-07-17
DISCOVER-2 is a randomized, double-blind, multi-center phase 3 clinical study that evaluates the efficacy and safety of TREMFYA subcutaneous injection in patients with active PsA, including patients who have previously received one or two biological tumors Necrosis factor inhibitor therapy .
-
Where is the treatment of new crown drugs?
Time of Update: 2021-07-17
Clinical report 2: On December 2, 2020, the "New England Journal of Medicine" released the World Health Organization (WHO) "Unity Trial" report [4], the results showed: 4 kinds of experimental drugs-Redecivir, Hydroxy Chloroquine, lopinavir/ritonavir, and interferon all had little improvement in the overall mortality, risk of mechanical ventilation, and length of stay in hospitalized patients with new coronavirus infection .
-
Merck's Keytruda EU approved its first pediatric indication: treatment of relapsed or refractory cHL
Time of Update: 2021-07-16
On March 17, Merck announced that the European Commission has approved the expansion of the anti-PD-1 therapy Keytruda (pembrolizumab) as a monotherapy for the treatment of 3 years and older, failure of autologous stem cell transplantation (ASCT), or unsuitable ASCT In the case of adult and pediatric patients with relapsed or refractory classic Hodgkin’s lymphoma (cHL) who have received at least 2 therapies .
-
Merck's Keytruda treatment of urothelial cancer was rejected by NICE in the UK
Time of Update: 2021-07-16
On March 18, the National Institute of Health and Care Excellence (NICE) issued the second final assessment document, rejecting Merck’s Keytruda for the treatment of advanced bladder cancer .
-
TOP 10 most noteworthy clinical project results in 2021
Time of Update: 2021-07-16
The Phase 2 study of Enhertu combined with hormone drugs in the treatment of early HER2 low-level tumor patients is expected to announce the results in the second half of this year .
-
Eli Lilly Announces Results of Verzenio Phase III MonarchE Clinical Trial PRO Patient Report
Time of Update: 2021-07-16
The results of the trial showed that Verzenio combined with standard endocrine therapy significantly reduced the risk of breast cancer recurrence or death in patients compared with standard endocrine therapy .
-
Optimizing the layout: drug parameters that new drug R&D workers should pay attention to
Time of Update: 2021-07-16
1. The nitrogen atom of piperidine is methylated to obtain compound 9, which improves the ability to penetrate the blood-brain barrier, making the concentration in the central nervous system 0.
-
LAV and Jingwei China jointly bet, where is the strength of the fixed-point coupling technology?
Time of Update: 2021-07-14
GlycoConnect technology can use natural antibody glycans to achieve site-specific coupling and stable toxin attachment, and produce ADC drugs with DAR 1, 2, and 4 .
